BiotechTube

Nitrous Oxide + Nitrogen

Phase 2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obsessive-Compulsive Disorder

Conditions

Obsessive-Compulsive Disorder

Trial Timeline

Apr 17, 2021 → Oct 1, 2027

NCT ID
NCT03826693

About Nitrous Oxide + Nitrogen

Nitrous Oxide + Nitrogen is a phase 2 stage product being developed by Brain Biotech for Obsessive-Compulsive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03826693. Target conditions include Obsessive-Compulsive Disorder.

What happened to similar drugs?

2 of 4 similar drugs in Obsessive-Compulsive Disorder were approved

Approved (2) Terminated (0) Active (2)
✅pregabalin + PlaceboPfizerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
🔄Troriluzole + PlaceboBiohavenPhase 3
🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03826693Phase 2Recruiting

Competing Products

8 competing products in Obsessive-Compulsive Disorder

See all competitors
ProductCompanyStageHype Score
Bitopertin + Placebo + SSRIRochePhase 2
35
pregabalin + PlaceboPfizerApproved
43
Sertraline + Levetiracetam + PlaceboUCBPhase 2/3
30
Escitalopram + Placebo oral tabletLundbeckApproved
44
Valbenazine + PlaceboNeurocrine BiosciencesPhase 2
39
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 2/3
32